Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing novel small molecule therapeutics for diseases with unmet medical needs, primarily in the U.S. market. The company relies on strategic alliances with Japanese pharmaceutical companies to license product candidates. As of the reporting date, the company had no products approved for commercial sale and generated no revenue from product sales.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(21.9) million | $(48.9) million |
| Research & Development Expenses | $(13.8) million | $(42.1) million |
| General & Administrative Expenses | $(8.8) million | $(11.4) million |
| Cash, Cash Equivalents & Marketable Securities | $19.3 million | $70.6 million |
| Long-Term Investments (ARS) | $24.0 million | $0 (reclassified) |
| Working Capital | $17.8 million | $65.9 million |
| Accumulated Deficit | $(227.0) million | $(205.1) million |
Note: The company reported an impairment charge, net on long-term investments and assets of $(1.3) million in 2008, driven by a $7.1 million write-down of Auction Rate Securities (ARS) offset by a $5.8 million gain on an ARS Put option.
Material Changes vs. Prior Period
- Significant Reduction in R&D Spend: Research and development expenses decreased by $28.3 million (67%) from 2007 to 2008. This was primarily due to the termination of the Phase III trial for MN-001 (bronchial asthma), the completion of the Phase II trial for MN-166 (multiple sclerosis), and the cessation of development for MN-305 (insomnia).
- Investment Portfolio Restructuring: Due to the global credit crisis and failed auctions, the company reclassified its Auction Rate Securities (ARS) from "marketable securities available-for-sale" to "long-term investments." A $7.1 million other-than-temporary impairment was recorded on these assets.
- Liquidity Position: Cash and cash equivalents decreased by approximately $51 million year-over-year, largely due to the net operating loss and the reclassification of investments. However, the company secured an $18.1 million loan facility against its ARS portfolio in early 2009 to bolster liquidity.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management has prioritized two product candidates: MN-221 (acute exacerbations of asthma) and MN-166 (multiple sclerosis).
- MN-221: The company is actively pursuing independent development in the U.S., having initiated a Phase II emergency department trial in early 2009. Interim data showed a reduced hospitalization rate compared to standard care alone.
- MN-166: Following the completion of a two-year Phase II trial in 2008, the company is not planning further significant clinical development until a strategic collaboration is secured to fund Phase III trials.
Liquidity Outlook
Management believes existing cash and cash equivalents as of December 31, 2008, are sufficient to fund operations through at least December 31, 2009. Future capital needs will be met through strategic collaborations, equity sales, or debt financing.
Key Risks and Contingencies
- Auction Rate Securities (ARS) Illiquidity: The company holds approximately $24 million in ARS that have experienced failed auctions. While the company has a "Put" right to sell these to UBS at par value starting in June 2010, there is no assurance of liquidity before that date.
- Dependence on Partnerships: The commercialization of MN-166 is contingent on securing a strategic partner. Failure to do so could delay or halt development.
- Regulatory Approval: No product candidates have received FDA approval. Clinical trials carry a high risk of failure, and regulatory approval is uncertain.
- Intellectual Property: The company relies on licensed patents. Some key patents (e.g., for MN-001) have expired or are expiring, and the company lacks composition of matter patents for MN-166, relying instead on method-of-use patents.
Investor Verification Checklist
- ARS Liquidity Status: Verify the current status of the failed auctions for the $24 million ARS portfolio and the enforceability of the UBS "Put" option exercisable in 2010.
- MN-221 Trial Progress: Confirm enrollment rates and final results of the Phase II emergency department trial for MN-221 initiated in early 2009.
- Strategic Partnership for MN-166: Assess the company's progress in securing a partner to fund Phase III development for MN-166, as internal funding for this program has been paused.
- Cash Burn Rate: Monitor quarterly cash flow statements to ensure the runway extends beyond the projected end of 2009, given the high costs of clinical trials.
- License Milestone Obligations: Review upcoming milestone payment triggers under license agreements with Kissei Pharmaceutical and Kyorin Pharmaceutical, which could total over $94 million if all milestones are achieved.